Clinical Trial Update: NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care

View source ↗

Summary

A non-interventional study (NIS) is recruiting to examine disease activity in systemic lupus erythematosus patients treated with subcutaneous anifrolumab in rou…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• SAPHNELO (ANIFROLUMAB-FNIA)

Snippet

Sponsor: AstraZeneca | Conditions: Lupus Erythematosus, Systemic | Status: RECRUITING